NOTCH2 and B-cell chronic lymphocytic leukemia: In addition, CLL cells with trisomy 12 potentially develop primary resistance to venetoclax due to specific alterations in the IRF4/NOTCH2 axis, and the initial treatment phase has been unsatisfactory (42, 43), suggesting that we should choose another appropriate drug if trisomy 12 of CLL cells occurs.